SCHEMBL2533671

SCHEMBL2533671

Clc1cccc(Oc2[c]cccc2)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
RHEB Q15382 1/20 0.41
SLC6A2 P23975 4/20 0.38
SLC6A4 P31645 4/20 0.38
SLC6A3 Q01959 4/20 0.38
HTR1A P08908 2/20 0.38
DPP4 P27487 1/20 0.34
NPSR1 Q6W5P4 3/20 0.34
TSHR P16473 2/20 0.33
CYP2D6 P10635 2/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
TTR P02766 1/20 0.33
HSP90AA1 P07900 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345301 0.87 HPGD (0.41) ALDH1A1RHEBSLC6A2SLC6A4SLC6A3
SCHEMBL4832971 0.83 KDM4E (0.37) SLC6A2SLC6A4SLC6A3HTR1ADPP4
SCHEMBL1345258 0.81 RARG (0.39) ALDH1A1SLC6A2HTR1ADPP4TSHR
SCHEMBL10965997 0.80 KDM4E (0.35) ALDH1A1MAPTKDM4E
SCHEMBL8115982 0.79 ALDH1A1 (0.40) ALDH1A1RHEBSLC6A2SLC6A4SLC6A3
SCHEMBL8125202 0.77 ALDH1A1 (0.41) ALDH1A1RHEBSLC6A2SLC6A4SLC6A3
SCHEMBL8115681 0.77 ALDH1A1 (0.38) ALDH1A1RHEBSLC6A2SLC6A4SLC6A3
SCHEMBL8131299 0.77 SLC6A2 (0.41) ALDH1A1RHEBSLC6A2SLC6A4SLC6A3
SCHEMBL8129407 0.76 ALDH1A1 (0.42) ALDH1A1RHEBSLC6A2SLC6A4SLC6A3
SCHEMBL8129015 0.76 HTR1A (0.43) ALDH1A1RHEBSLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044035-B2 Pharmaceutical compositions of pyrimidine-2,4,6-triones UNIVERSITE DE LIEGE (BE) 2011-10-25 US disclosed
US-20100261672-A1 PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES UNIVERSITE DE LIEGE (BE) 2010-10-14 US disclosed
US-20070191404-A1 Pharmaceutical compositions of pyrimidine-2,4,6-triones HOFFMANN-LA ROCHE INC. 2007-08-16 US disclosed
EP-1735007-A2 CYCLODEXTRIN INCLUSION COMPLEXES OF PYRIMIDINE-2,4,6-TRIONES F.HOFFMANN-LA ROCHE AG (CH) 2006-12-27 EP disclosed
WO-2005097058-A2 CYCLODEXTRIN INCLUSIONS COMPLEXES OF PYRIMIDINE-2,4,6-TRIONES F. HOFFMANN-LA ROCHE AG (CH) 2005-10-20 WO disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 EP disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191404-A1 Pharmaceutical compositions of pyrimidine-2,4,6-triones TK1, TYMP, TYMS ALDH1A1 3619/4885RHEB 3824/4885SLC6A2 3251/4885
US-20100261672-A1 PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES TYMP, DPYD, TYMS ALDH1A1 3179/4885RHEB 4776/4885SLC6A2 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.